Treatment options for older adults with Acute Myeloid Leukaemia and Myelodysplasia are limited. Although stem cell transplantation remains one of the most effective treatments it is associated with severe side effects which have until recently prevented its use in older adults. Recent studies in Europe appear to have identified a new form of transplant regimen which is associated with improved outcomes in older patients; we therefore propose to compare the new FLAMSA-BU transplant with currently used transplant regimens, allowing us to compare the benefits in terms of toxicity, disease relapse and overall survival.
Please note that the trials team cannot give individuals clinical advice. Patients and their families should contact their treating physician to discuss trials for which they may be eligible
Chief Investigator: Professor Charles Craddock
|
|
| Sponsor: The University of Birmingham |
|
| Funders: Bloodwise |
|
Disease Site: Acute Myeloid Leukaemia and Myelodysplasia
|
|
Trial Type: Clinical Trial of an Investigational Medicinal Product
|
|
| Status: Follow-up |
|
UKCRN Study ID: 14772
|
|
| Open to new sites? No |
|
Recruitment start date: 16/10/2013
|
|
Recruitment end date: 08/02/2017
|
|
| CRCTU Trial Management Team: Haematology |
|
| Trial E-mail Address: Figaro@trials.bham.ac.uk |
|